BioSyent (CVE:RX) Share Price Passes Above 50-Day Moving Average – Time to Sell?

BioSyent Inc. (CVE:RX) shares passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of C$11.14 and traded as high as C$11.21. BioSyent shares last traded at C$11.20, with a volume of 880 shares traded.

BioSyent Stock Performance

The company has a fifty day moving average price of C$11.12 and a two-hundred day moving average price of C$11.05. The firm has a market cap of C$128.10 million, a price-to-earnings ratio of 18.18 and a beta of 0.93. The company has a debt-to-equity ratio of 2.90, a current ratio of 3.92 and a quick ratio of 6.91.

Insider Buying and Selling at BioSyent

In other BioSyent news, insider FAX Capital Corp. sold 112,400 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of C$11.28, for a total value of C$1,267,557.28. Also, Senior Officer Robert Joseph March sold 4,775 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total transaction of C$55,628.75. In the last three months, insiders sold 117,707 shares of company stock valued at $1,329,581. 33.65% of the stock is owned by insiders.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.